ClinicalTrials.gov
public full text
Public Domain
Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease
This is multicentre, proof of concept, randomized, double-blind, parallel-group, placebo-control study in 40 Parkinson's Disease (PD) patients. Patients will be randomized in 2 groups receiving Bumetanide or placebo for 4 months: * Group 1 (20 PD patients): bumetanide * Group 2 (20 PD patients): placebo intake identically to group 1.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients#1138692
- Simulated Driving Study in Restless Legs Syndrome#807551
- Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients#856567
- A Single and Repeat Dose Trial in Participants With Hepatic Impairment#1115059
- Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment#993625
Record · ID 1171377
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive